Abiomed (NSDQ:ABMD) today said it appointed Charles Simonton as VP and chief medical officer.
Simonton most recently served as chief medical officer and divisional VP of global medical affairs at Abbott Vascular where he led programs that resulted in FDA approval of carotid stents, MitraClip and Absorb BVS. He has also spent almost 30 years as an interventional cardiologists working with complex cardiac and vascular patients.
“I am excited to be a part of Abiomed’s dedicated team focused on developing innovative medical devices. Over the years, I have become very familiar with the benefits of Impella and its ability to unload the heart and have seen how it is transforming the standard of care. I am impressed with Abiomed’s talent, culture, and mission and I am thrilled to be joining the company,” Simonton said in a news release.
Simonton replaces Seth Bilazarian who served as VP and chief medical officer since 2015. Bilazarian will assume medical leadership of Abiomed’s physician education and training programs as vice president of medical education and training.
“The addition of Dr. Chuck Simonton makes our world-class medical office even stronger,” president and CEO Michael Minogue said. “Chuck’s impressive record of accomplishments and expertise will complement Seth’s leadership in advancing our education and training programs and help Abiomed rise to the next level for our patients and physicians.”
